Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06354465 · ClinicalTrials.gov registry record

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

A clinical trial of Opioid Use Disorder and Treatment Adherence and Compliance, sponsored by Lifespan.

Recruiting
Registry status
25
Enrollment target
1
Study location

NCT06354465 is a study of Opioid Use Disorder and Treatment Adherence and Compliance that is actively recruiting participants, run by Lifespan. The registered enrollment target is 25 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06354465, a study of Opioid Use Disorder and Treatment Adherence and Compliance, is actively recruiting participants, sponsored by Lifespan.

RECRUITING
Registry status
25 participants
Enrollment target
1
Study location

Study Summary

This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.

Study Locations (1)

Rhode Island

  • Rhode Island Department of Corrections - Cranston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2023-07-01
Est. Completion 2024-07-01

Sponsor

Lifespan

18 total trials

What the Registry Record Tells You About NCT06354465

The ClinicalTrials.gov registry entry for NCT06354465 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The listed sponsor is Lifespan, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT06354465 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT06354465 about?

NCT06354465 is a clinical study titled "Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews". This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a...

What is the current status of trial NCT06354465?

This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2023-07-01. Estimated completion is 2024-07-01.

What conditions does trial NCT06354465 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Treatment Adherence and Compliance, Criminal Justice.

Who is sponsoring clinical trial NCT06354465?

This trial is sponsored by Lifespan, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06354465 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.